RDInvesting Provides Investors with Free In-Depth Equity Reports on FDX, IMUC, PANW and SKULadmin
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
FedEx Corporation (NYSE: FDX) shares gained 1.14 percent to close at $137.90 a share Friday. The stock traded between $137.01 and $138.88 on volume of 2.58 million shares traded. Analysts at Raymond James have recently upgraded the company’s rating to “strong buy” from “outperform”. Shares of FedEx have gained approximately 50.0 percent year-to-date.
Find out more about FedEx including full access to the free equity report at:
ImmunoCellular Therapeutics Ltd. (NYSEMKT: IMUC) shares declined 7.27 percent to close at $1.02 a share Friday. The stock traded between $0.99 and $1.10 on volume of 6.26 million shares traded. Analysts at MLV Capital have recently downgraded the company’s rating to “hold” from “buy”. Shares of ImmunoCellular have fallen approximately 60.0 percent year-to-date.
Find out more about ImmunoCellular including full access to the free equity report at:
Palo Alto Networks Inc. (NYSE: PANW) shares gained 3.55 percent to close at $53.94 a share Friday. The stock traded between $51.99 and $54.11 on volume of 1.90 million shares traded. Analysts at Zacks have recently upgraded the company’s rating to “neutral” from “underperform”.
Find out more about Palo Alto Networks including full access to the free equity report at:
Skullcandy Inc. (NASDAQ: SKUL) shares gained 0.74 percent to close at $5.42 a share Friday. The stock traded between $5.34 and $5.50 on volume of 131,608 shares traded. Analysts at TheStreet have recently downgraded the company’s rating to “sell” from “hold”. Shares of Skullcandy have fallen approximately 30.0 percent year-to-date.
Find out more about Skullcandy including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Posted: December 16th, 2013 under ACCESSWIRE.